Celularity Inc. (NASDAQ: CELU) filed its Annual Report on Form 10-K for fiscal year 2025 and regained compliance with Nasdaq listing requirements, the company announced.

The regenerative medicine company received notification from Nasdaq on April 16 that it was not in compliance due to the delayed filing of its Form 10-K. After filing the report on April 30, Nasdaq notified Celularity on May 1 that it complies with Listing Rule 5250(c)(1) and the matter is closed.

The company has undertaken several restructuring initiatives, including out-licensing its biomaterials portfolio and reducing recorded liabilities by approximately $13 million. These actions resulted in personnel realignments and the departure of certain executive officers.

"We are pleased to have completed our Form 10-K filing and regained compliance with Nasdaq's reporting requirements," said Robert J. Hariri, Chairman and Chief Executive Officer. "This reflects the significant progress we are making as we build a stronger, more focused and more resilient company for the future."

Celularity develops cell therapies derived from postpartum placenta, focusing on treatments targeting aging and age-related diseases. The company stated it will concentrate resources on its longevity and cell therapy platforms following the organizational changes.

The information is based on a company press release.